Cargando…
RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
BACKGROUND: Thyroid eye disease (TED) causes orbital soft tissue expansion. Teprotumumab, a monoclonal antibody to the IGF-1R reduces orbital soft tissue swelling in TED. In this study, we quantified the changes to pan facial soft tissue volumes, following treatment with Teprotumumab. METHODS: In th...
Autores principales: | Ugradar, Shoaib, Douglas, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628256/ http://dx.doi.org/10.1210/jendso/bvac150.1781 |
Ejemplares similares
-
RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022) -
Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2021) -
LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022) -
PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022) -
SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)